NeuBase Therapeutics Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing

October 15, 2022

https://www.globenewswire.com/news-release/2022/10/14/2534944/0/en/NeuBase-Therapeutics-Announces-Strategic-Restructuring-Focused-on-Advancing-Its-Platform-in-Gene-Editing.html

PITTSBURGH, Oct. 14, 2022 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq:NBSE) (“NeuBase” or the “Company”) today announced plans to restructure the Company to focus on the advancement of its platform in gene editing. Implementation of this strategy, which follows a strategic internal review by the Company’s board of directors and management team, includes several initiatives aimed at streamlining the organization, reducing operating expenses, preserving capital, and creating long-term shareholder value.

Read more at globenewswire.com

Related news for (NBSE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.